BRKR Bruker Corporation

At Pittcon 2006, Bruker Daltonics today announces the release of its novel MALDI BioTyper(TM) system for the identification and classification of microorganisms using protein 'fingerprints' measured by MALDI-TOF mass spectrometry. The characteristic protein expression patterns of microorganisms, such as bacteria, yeasts and fungi, can be analyzed with the new MALDI BioTyper system. The remarkable reproducibility of the MALDI BioTyper is based on the measurement of high-abundance proteins, including many ribosomal proteins. As ribosomal proteins are part of the cellular translational machinery, they are present in all living cells. As a result, the MALDI BioTyper protein fingerprints are not significantly influenced by variability in environmental or growth conditions. This is a crucial advantage of this new microbiology method, as it allows the generation of robust MALDI BioTyper libraries of microorganisms. A more detailed application note is available at www.bdal.de/biotyper The MALDI BioTyper represents an excellent complement to classical microbiological identification and classification techniques, and to modern PCR-based techniques. In contrast to other approaches, the MALDI BioTyper does not require any initial assessment like gram staining, oxidase test of unknown samples, choice of PCR primers or usage of selective growth media. Applications of the MALDI BioTyper include taxonomical research on microorganisms, infectious disease research, as well as microorganism detection and identification in environmental analysis, food safety and water quality. Using standardized MALDI BioTyper methods, after an overnight culture growth, cell material can either be directly transferred onto a MALDI-TOF target plate, or it can be analyzed after a rapid organic extraction procedure. Excellent reproducibility can be achieved routinely even by inexperienced users. Easy and cost-effective sample preparation combined with rapid TOF data acquisition in seconds allows the analysis of hundreds of samples within a day. Redundant measurements are possible to further increase the level of confidence. The MALDI BioTyper bioinformatics package performs the microorganism identification and classification based on MALDI-TOF proteomic signatures. The MALDI BioTyper software carries out all necessary data processing steps leading from raw spectra to peak lists. The generation of reference spectra for individual strains is automated, but the software also allows for expert interaction. Microorganism identification is performed by pattern matching between reference spectra and MALDI-TOF profiles of unknown strains. The analysis results are visualized in an intuitive graphical user interface. In addition to enabling the identification of known microorganisms, the MALDI BioTyper software offers a variety of advanced algorithms for the characterization of unknown microorganisms, including clustering and phylogenetic dendrogram construction. This unique feature allows the protein signature classification of unknown species and strains, and uniquely complements taxonomical and phylogenetic approaches, such as ribosomal DNA sequencing. The MALDI BioTyper typically achieves identification at the genus or species level. In many cases even different microbial strains can be distinguished. Dr. Thomas Maier, the Bruker Daltonics MALDI BioTyper Project Manager, said: "The idea of the MALDI BioTyper is to combine easy sample preparation, state-of-the-art instrumentation and robust data analysis tools into a next-generation technique for the fast, convenient and cost-effective identification of microbial strains. Our customers are very impressed by the facile and cost-effective sample preparation used in our unique protein signature approach for unequivocal microbial identification." Dr. Markus Kostrzewa, Director of Clinical Proteomics R&D at Bruker Daltonics, explained further: "An attractive aspect of the MALDI BioTyper is that it fits seamlessly with our other MALDI-TOF based CLINPROT(TM) clinical proteomics applications, such body-fluid profiling, protein biomarker identification and validation, as well as MALDI molecular imaging. The MALDI BioTyper is a further step in bringing our mass spectrometry-based solutions into biology laboratories where the same instrument can be used for multiple workflows in life science and clinical research applications." Pittcon 2006, the 57th Pittsburgh Conference and Exposition on Analytical Chemistry and Applied Spectroscopy, is being held from March 13-16 in Orlando, Florida in the Orange County Convention Center. Bruker Daltonics will exhibit at booth #3155. ABOUT BRUKER BIOSCIENCES (NASDAQ: BRKR) Bruker BioSciences Corporation, headquartered in Billerica, Massachusetts, is the publicly traded parent company of Bruker Daltonics Inc. and Bruker AXS Inc. Bruker AXS is a leading developer and provider of life science, materials research, and industrial X-ray analysis tools. Bruker Daltonics is a leading developer and provider of innovative life science tools based on mass spectrometry. Bruker Daltonics also offers a broad line of nuclear, biological and chemical (NBC) detection products for defense and homeland security. For more information, please visit www.bruker-biosciences.com CAUTIONARY STATEMENT Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's reorganization strategies, integration risks, failure of conditions, technological approaches, product development, market acceptance, cost and pricing of the Company's products, changes in governmental regulations, capital spending and government funding policies, FDA and other regulatory approvals to the extent applicable, competition, the intellectual property of others, patent protection and litigation. These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our respective annual reports on Form 10-K for the year ended December 31, 2004, our most recent quarterly reports on Form 10-Q, and our current reports on Form 8-K. We disclaim any intent or obligation to update these forward-looking statements.